A Phase I, Prospective, Open-Label, Comparison Study of Lymphoseek and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Cancer of the the Endometrium Who Are Undergoing Lymph Node Dissection

Trial Profile

A Phase I, Prospective, Open-Label, Comparison Study of Lymphoseek and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Cancer of the the Endometrium Who Are Undergoing Lymph Node Dissection

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Tc 99m tilmanocept (Primary)
  • Indications Endometrial cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jun 2017 Planned End Date changed from 1 Dec 2016 to 1 Nov 2017.
    • 06 Jun 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Nov 2017.
    • 11 May 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top